Description
Retatrutide (often referred to in research contexts similarly to “Upret,” a 39-amino acid peptide) is an investigational triple-hormone receptor agonist currently in phase 3 clinical trials. It is recognized as a potentially superior weight-loss agent compared to current GLP-1 and dual-agonist therapies.
Key Advantages of Retatrutide (Triple-Action Peptide):
- Triple-Receptor Mechanism: Unlike semaglutide (GLP-1) or tirzepatide (GIP/GLP-1), retatrutide activates three receptors: GLP-1 (appetite suppression), GIP (insulin optimization), and Glucagon (increased energy expenditure).
- Unprecedented Weight Loss Results: In phase 2 trials, participants lost up to 24.2% of their body weight over 48 weeks. Some studies have shown an average weight loss of up to 28.7% over 68 weeks, exceeding the performance of current approved medications.
- Increased Fat Burning (Energy Expenditure): The addition of glucagon receptor agonism increases the basal metabolic rate, which helps the body burn more calories and fat compared to therapies that primarily rely on appetite reduction.
- Substantial Visceral Fat Reduction: Research suggests that high-dose retatrutide can lead to a 45–48% reduction in visceral fat tissue (deep abdominal fat associated with high metabolic risk).
- Improved Metabolic Health: Beyond weight loss, it has been shown to improve insulin sensitivity and significantly reduce hemoglobin A1c (HbA1c), with up to 72% of pre-diabetic patients in studies returning to normal blood sugar levels.
- Potential Additional Benefits: Studies suggest potential improvements in cardiovascular health (blood pressure reduction), liver health (significant reductions in liver fat), and reduction of knee osteoarthritis pain.
Reviews
There are no reviews yet.